ONA-389

About Ona Therapeutics

Ona Therapeutics is a private, pre-clinical stage biotech focused on developing novel antibody drug conjugates (ADCs) for metastatic and refractory cancers. The company's core strategy is to identify unique therapeutic targets by analyzing the molecular changes in cancers from patients who have become resistant to standard treatments, thereby addressing a critical unmet need. With a seasoned leadership team and backing from a €30M Series A round, Ona is advancing two wholly-owned internal programs, including a lead ADC for refractory breast cancer. The company represents a targeted approach in the competitive ADC landscape, aiming to improve outcomes for advanced cancer patients.

Therapeutic Areas